LONDON, October 6, 2014 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 03, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,009.69, up 1.24% and the NASDAQ Composite closed at 4,475.62, up 1.03%. The S&P 500 finished the session 1.12% higher at 1,967.90. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 745.09, up 1.97%, with the index advancing 3.29% in the previous three months. Register for your complimentary reports on these five stocks at:
AstraZeneca PLC's stock edged 0.81% higher, to close the day at $69.84. The stock recorded a trading volume of 1.02 million shares, below its three months average volume of 2.24 million shares. The company's shares oscillated between $69.39 and $69.95 during the session. Over the last three trading sessions and over the past one month, AstraZeneca PLC's shares have fallen by 2.24% and 6.56%, respectively. However, the stock has gained 17.64% since the start of this year. The company's stock is trading above its 200-day moving average of $69.59, while the 200-day moving average is below AstraZeneca PLC stock's 50-day moving average of $72.42. Additionally, the stock has a Relative Strength Index (RSI) of 37.84. Sign up and read the free notes on AZN at:
On Friday, shares in Novartis AG recorded a trading volume of 1.61 million shares, higher than its three months average volume of 1.23 million shares. The stock ended the day at $92.37, which was 0.72% below its previous day's closing of $93.04, and registered an intraday range of $91.90 and $92.65. Although Novartis AG's stock has fallen by 1.87% in the previous three trading sessions, it has advanced 1.03% in the last three months and 14.92% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $90.60 and $86.30, respectively. Furthermore, shares of Novartis AG have an RSI of 47.23. The complimentary notes on NVS can be downloaded as in PDF format at:
Salix Pharmaceuticals Ltd.'s stock gained 1.18% to end Friday's session at $152.87. The stock recorded a trading volume of 6.01 million shares, much above its three months average volume of 1.66 million shares. The company's shares fluctuated between $152.24 and $162.00 during the session. Shares of the company traded at a PE ratio of 85.38. Salix Pharmaceuticals Ltd.'s shares have surged 69.97% since the beginning of 2014. However, the stock has fallen by 2.16% over the previous three trading sessions and 1.06% in the last one month. The company's stock is trading above its 50-day and 200-day moving averages. Salix Pharmaceuticals Ltd.'s 50-day moving average of $149.08 is above its 200-day moving average of $118.70. Additionally, the stock has an RSI of 47.27. Register for free on Investor-Edge and access the latest research on SLXP at:
On Friday, shares in Inovio Pharmaceuticals Inc. fluctuated between $10.45 and $11.29 before ending the session 5.55% higher at $11.03. The stock reported a trading volume of 2.64 million shares, higher than its three months average volume of 1.38 million shares. Inovio Pharmaceuticals Inc.'s shares have gained 11.98% in the previous three trading sessions, 3.86% in the last one month, and 3.57% in the past three months. The company's stock is trading above its 50-day and 200-day moving averages of $10.31 and$10.68, respectively. Moreover, shares of Inovio Pharmaceuticals Inc. have an RSI of 60.71. The complete research on INO is available for free at:
CTI BioPharma Corp.'s stock finished Friday's session 0.41% higher at $2.42. A total of 0.61 million shares were traded, which was below its three months average volume of 1.16 million shares. The stock vacillated between $2.39 and $2.44 during the session. Over the last one month and over the previous three months, CTI BioPharma Corp.'s shares have fallen by 1.63% and 19.33%, respectively. However, from the beginning of 2014, the stock has gained an upside of 26.70%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $2.94 is greater than its 50-day moving average of $2.53. CTI BioPharma Corp.'s stock has an RSI of 43.23. Free in depth research on CTIC is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.